report adj ep ahead consensu due tax although net revenue miss
retail usa beat top- bottom-lin expect announc cost cut
initi w/ save expect fuel growth would remain sidelin
unsur store-in-stor partnership strategi fit value-bas care
environ w/ earli inning
streetaccount thomson eikon cowen compani
report adj ep y/i ahead consensu
estim beat attribut lower expect tax rate
estim contribut quarter oper miss appear come
under-perform retail pharmaci intern pharmaci wholesal
net revenu y/i fell short expect due
lower expect revenu retail pharmaci intern pharmaci
retail usa pharmaci compstore y/i same-stor prescript
y/i retail compstore y/i primarili due continu de-emphasi
select product tobacco neg bp impact difficult y/i
comp relat impact hurrican strong flu season last year
management re-affirmed adj ep guidanc impli y/i growth
constant currenc basi management continu expect share repurchas
well adj effect tax rate also plan deploy
toward store labor invest
pleas see page report import disclosur
market perform rate think compani weakli posit
transit toward value-bas care rel peer other pharma
suppli chain manag care industri consolid integr medic
pharmaci data stand still reliant tradit retail pharmaci
model believ leav expos potenti disrupt also
think ownership acquisit aet rather partnership open health
hub necessari realiz benefit cost trend improv without
see potenti margin distribut channel greater risk
disrupt furthermor manag consist meet exceed adj ep
estim fare well base oper metric think indic
challeng macro environ
y/i top-lin growth driven
growth part acquisit
alliancerx includ fep contract
margin pressur continu
share repo
y/i top-lin growth high-singl
lower expect margin pressur
share repo greater
benefit disrupt cvs/aet
y/i top-lin growth low-singl
greater expect margin pressur
walgreen oper largest drugstor chain compani sell product
servic retail drugstor mail telephon on-line
channel within store walgreen sell prescript non-prescript drug
well gener merchandis includ household item conveni fresh food
person care beauti care photofinish candi primarili within retail locat
walgreen oper take clinic walgreen also oper specialti infus
respiratori servic mail servic
announc launch transform cost manag program target
annual cost save excess end third year base convers
management seem cost save drop bottom line
use fuel growth program includ division optim initi
global smart spend global smart organ digit enterpris
transform long-term capabl division optim alreadi begun includ
cost reduct pharmaceut wholesal segment chile mexico
retail busi addit initi global smart spend smart organ
program initi focus retail pharmaci usa segment retail busi
 global function management anticip aspect transform cost
manag program result restructur special charg
appear earli stage store-in-stor partnership strategi mani
partnership still pilot phase unsur strategi fit
value-bas care environ base know far think
strategi leav weakli posit transit toward value-bas care rel
peer mani becom vertic integr addit given
announc partnership remain pilot phase difficult us gain comfort
regard potenti impact particularli told management
great deal variabl partnership agreement structur
said think could becom construct gain greater visibl
partnership strategi think expand relationship could
opportun particularli result greater align affect care
share upsid
maintain adj ep estim slightli lower adj ep
estim slightli lower price target base
revis dcf analysi impli share trade adj ep
estim current multipl
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per year end august cowen
million except per-shar data
compani report cowen compani
fifo cost fifo gross fifo gross chang lifo lifo gross lifo gross equiti earn ab- adjust equiti earn adjust oper adjust oper expens pre-tax pre-tax tax incom tax tax earn equiti method net earn non-controlling adjust net total net averag dilut adjust chang gross gross oper year end august cowen
million except per-shar data
compani report cowen compani
fifo cost fifo gross fifo gross chang lifo lifo gross lifo gross equiti earn ab- adjust equiti earn adjust oper adjust oper expens pre-tax pre-tax tax incom tax tax earn equiti method net earn non-controlling adjust net total net averag dilut adjust chang gross gross oper cowen
million
compani report cowen compani
asset cash account receiv current current properti intang non-curr total current liabil short-term trade account accru expens incom current long-term defer incom non-curr stockhold equiti common paid-in employe stock loan retain accumul comprehens treasuri non-controlling total stockhold total liabil stockhold short-term liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end august cowen
million
compani report cowen compani
income/ loss flow oper activ depreci gain previous held equiti interest- share base compens unreal gain fair valu adjustments- defer incom invest impair chang oper asset liabil receiv current non-curr account accru expens incom non-curr net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari oper capit owner financ non-recur exclud non-recur itemsfor year end august cowen
million
compani report cowen compani
flow oper activ net adjust reconcil net earn net cash depreci loss allianc boot call sale business- defer incom stock compens incom tax save employe stock plans- chang oper asset liabil account receiv current trade account accru expens incom non-curr asset net cash provid oper flow invest activitiesaddit properti proce sale leaseback transactions- purchas short-term invest held proce short-term invest held purchas short-term invest avail sale- proce sale short-term invest avail sale- return invest restrict cash- proce sale busi intang asset acquisit net cash payment proce sale invest invest allianc boots- net cash use invest flow financ activitiesnet payment short-term borrowings- payment long-term proce financ issuanc long-term debt- stock proce relat employe stock dividend net cash provid use financ effect exchang rate chang cash cash equivalents- chang equivalentsnet decreas cash cash cash equival begin cash equival end year end august cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
see number risk associ drug retail space industri highli
competit retail drugstor chain independ pharmaci mail-ord provid
well retail includ groceri store mass merchant warehous club on-line
store compet space could pressur front-end sale margin
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind part believ
could concern around sustain high growth area
believ impact ppaca expect increas volum could subdu
depend implement execut
number company-specif risk associ pt includ loss
share disrupt entiti wors expect reimburs pressur better
expect gener procur wbad meaning acquisit
